Second-generation antipsychotic and diabetes mellitus in children and adolescents


Submitted: 13 February 2017
Accepted: 15 November 2017
Published: 13 December 2017
Abstract Views: 2626
PDF: 1207
HTML: 349
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Carlo Ripoli Unit of Diabetology-I Pediatric Section, Department of Surgical Sciences, University of Cagliari, Italy.
  • Anna Paola Pinna Unit of Diabetology-I Pediatric Section, Department of Surgical Sciences, University of Cagliari, Italy.
  • Faustina Podda Unit of Diabetology-I Pediatric Section, Department of Surgical Sciences, University of Cagliari, Italy.
  • Roberta Zanni Centre for Pharmacological Therapy in Child and Adolescent Neuropsychiatry, Department of Neuroscience B.B. Brodie, University of Cagliari, Cagliari, Italy.
  • Maria Giada Tronci Centre for Pharmacological Therapy in Child and Adolescent Neuropsychiatry, Department of Neuroscience B.B. Brodie, University of Cagliari, Cagliari, Italy.
  • Anna Maria Nurchi Unit of Diabetology-I Pediatric Section, Department of Surgical Sciences, University of Cagliari, Italy.
Second generation antipsychotics (SGA) are used in children for the treatment of various psychiatric diseases, including pervasive developmental disorders. These drugs can cause metabolic effects as hyperglycemia and diabetes. A 16-year-old young-boy, diagnosed with autism, developed diabetes mellitus type 1 whilst he was on treatment with olanzapine (started 4 months before), clomipramine, valproic acid and lithium. The hypothesis of druginduced diabetes imposed olanzapine interruption and clozapine initiation. Insulin therapy was practiced, with progressive dosage reduction, until complete cessation of treatment after 13 months. Blood sugar and HbA1c levels remained stable for about a year and then increased again, requiring the introduction of metformin that improved glycemia. In children and adolescents assuming SGA serum glucose and lipid profile should always be assessed before therapy and then frequently monitored. Drug selection must consider family history and the individual risk. Molecule final choice remains equilibrium between efficacy and safety.

Ripoli, C., Pinna, A. P., Podda, F., Zanni, R., Tronci, M. G., & Nurchi, A. M. (2017). Second-generation antipsychotic and diabetes mellitus in children and adolescents. La Pediatria Medica E Chirurgica, 39(4). https://doi.org/10.4081/pmc.2017.149

Downloads

Download data is not yet available.

Citations